<DOC>
	<DOC>NCT00325780</DOC>
	<brief_summary>This study is a long-term follow-up protocol for patients who participated in study NK-104-3.01EU or study NK-104-3.02EU.</brief_summary>
	<brief_title>Long-Term Extension Study of Pitavastatin in Patients With Primary Hypercholesterolemia or Combined Dyslipidemia</brief_title>
	<detailed_description>Patients from the NK-104-3.01EU and NK-104-3.02EU studies will continue to receive either pitavastatin or the comparator statin for 1 year.</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Pitavastatin</mesh_term>
	<criteria>Patients have completed 12 weeks of treatment in Study NK104301 (NCT00249249) or NK104302 (NCT00309777) Patients who have not developed any treatment emergent and, in the opinion of the investigator, related adverse event (AE) of clinical significance where the investigator is uncomfortable with continuing the patient on therapy with pitavastatin. Patients who have been following a fat and cholesterol restrictive diet. Any conditions which may cause secondary dyslipidemia should be reassessed at the beginning of the followup study. Uncontrolled diabetes mellitus should be reassessed at the beginning of the followup study. Abnormal pancreatic, liver, or renal function Abnormal serum ALAT/SGPT/ALT, ASAT/SGOT/AST, or creatine kinase (CK) above the prespecified level Significant heart disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Kowa</keyword>
	<keyword>Hypercholesterolemia</keyword>
	<keyword>dyslipidemia</keyword>
	<keyword>pitavastatin</keyword>
	<keyword>NK-104</keyword>
	<keyword>Hypercholesterolemia or combined dyslipidemia</keyword>
</DOC>